Andrej Emanuel Cotman

Andrej Emanuel Cotman

Auto-generated profile, based on publicly available information

Andrej Emanuel Cotman

Faculty of Pharmacy University of Ljubljana Ljubljana Slovenia

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

12 January 2023 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
ACAndrej Emanuel Cotman
Andrej Emanuel Cotman
MDMartina Durcik
Martina Durcik
DTDavide Benedetto Tiz
Davide Benedetto Tiz
FFFederica Fulgheri
Federica Fulgheri
DSDaniela Secci
Daniela Secci
DKDanijel Kikelj
Danijel Kikelj
We have developed compounds with a promising activity against Acinetobacter baumannii and Pseudomonas aeruginosa, which are both on the WHO priority list of antibiotic-resistant bacteria. Starting from DNA gyrase inhibitor 1, we identified compound 27, featuring a 10-fold improved aqueous solubility, a 10-fold improved inhibition of topoisomerase IV from A. baumannii and P. aeruginosa, a 10-fold decreased inhibition of human topoisomerase IIα, and no cross-resistance to novobiocin. Cocrystal structures of 1 in complex with Escherichia coli GyrB24 and (S)-27 in complex with A. baumannii GyrB23 and P. aeruginosa GyrB24 revealed their binding to the ATP-binding pocket of the GyrB subunit. In further optimization steps, solubility, plasma free fraction, and other ADME properties of 27 were improved by fine-tuning of lipophilicity. In particular, analogs of 27 with retained anti-Gram-negative activity and improved plasma free fraction were identified. The series was found to be nongenotoxic, nonmutagenic, devoid of mitochondrial toxicity, and possessed no ion channel liabilities.

6 May 2019 in Organic Letters
Verified
Journal Article
Open access
ACAndrej Emanuel Cotman
Andrej Emanuel Cotman
MLMatic Lozinšek
Matic Lozinšek
BWBaifan Wang
Baifan Wang
MSMichel Stephan
Michel Stephan
BMBarbara Mohar
Barbara Mohar
A highly efficient enantio- and diastereoselective catalyzed asymmetric transfer hydrogenation via dynamic kinetic resolution (DKR–ATH) of α,β-dehydro-α-acetamido and α-acetamido benzocyclic ketones to ent-trans-β-amido alcohols is disclosed employing a new ansa-Ru(II) complex of an enantiomerically pure syn-N,N-ligand, i.e. ent-syn-ULTAM-(CH2)3Ph. DFT calculations of the transition state structures revealed an atypical two-pronged substrate attractive stabilization engaging the commonly encountered CH/π electrostatic interaction and a new additional O═S═O···HNAc H-bond hence favoring the trans-configured products.


23 December 2022 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
TCTing Chen
Ting Chen
WLWenjun Liu
Wenjun Liu
WGWei Gu
Wei Gu
SNShengtong Niu
Shengtong Niu
SLShouang Lan
Shouang Lan
XFXinqiang Fang
Xinqiang Fang

17 November 2025 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
IDIvan Džajić
Ivan Džajić
Tihomir TomašičTihomir Tomašič
Tihomir Tomašič
LPLuis A. Pardo
Luis A. Pardo
Lucija Peterlin MasicLucija Peterlin Masic
Lucija Peterlin Masic
ACAndrej Emanuel Cotman
Andrej Emanuel Cotman
Mitochondria-targeting technology, in the form of (lipophilic cation)–(small molecule) conjugates, was first discussed more than 50 years ago. Since then, the triphenylphosphonium (TPP) cation has become synonymous with the concept of a mitochondria-targeting moiety (MTM). The discovery of its ability to accumulate in mitochondria occurred alongside research on mitochondrial functions and the mechanisms underlying cation import. The recognition of intrinsic biological effects of TPP, apart from delivery of functional cargo, came much later, prompting the development of novel MTMs beyond the archetypal TPP. In this Perspective, we present the current understanding of the biological mechanisms of action of mitochondria-targeting conjugates, describe the methods used for their validation, and overview the recently developed novel mitochondria-targeting moieties. Building upon the recent advances, we propose a rational approach for the development of novel MTMs to be incorporated into the future MTM–linker–cargo therapeutics (MITACs, MITochondria-TArgeting Conjugates).